AOD-9604

At a glance

Overview

AOD-9604 consists of a tyrosine added to the 177–191 region of human growth hormone. That defined modified sequence matters because commercial descriptions often blur it with native Fragment 176–191. Early rodent work suggested effects on fat metabolism without the full growth-hormone receptor profile. Human obesity development subsequently failed to show adequate benefit over placebo in the large OPTIONS study. The molecule remains scientifically interesting, but that history should accompany claims about targeted fat loss rather than being replaced by selected positive animal results or unsupported claims of selective abdominal-fat reduction.

Supporting sources [1] [2] [3] [4]

How it works

Preclinical studies examined reduced lipogenesis, increased fat oxidation and lipolysis. One mouse and cell study found that AOD-9604 did not compete for the growth-hormone receptor or stimulate receptor-dependent proliferation in the tested system. This distinguishes it mechanistically from intact GH, but does not prove complete absence of endocrine or other effects in humans. A reliably validated human fat-loss mechanism has not emerged from the negative efficacy program.

Supporting sources [1] [2] [3] [4]

What animal studies found

Studies in obese rats and mice reported altered fat metabolism and reduced weight gain. The tested species, exposure and outcome matter: reducing weight gain in an animal model is not the same as producing clinically useful weight loss in adults.

Supporting sources [1] [2]

The important negative trial

FDA’s review describes the OPTIONS study, which enrolled 536 adults and found no significant weight-loss difference from placebo. The developer ended obesity development after that result. This is central evidence, not a minor omission from an otherwise proven treatment.

Supporting sources [3]

Relationship to Fragment 176–191

The analytical literature defines AOD-9604 as hGH 177–191 with an added N-terminal tyrosine. Native fragment nomenclature is not an assurance of that same sequence. Molecular identity must be established before evidence can be transferred between names.

Supporting sources [4]

What safety claims cannot establish

A lack of selected GH-like effects in preclinical experiments does not provide a complete human safety profile. Long-term use, injected preparations, immune responses and product purity require evidence specific to the formulation and route.

Supporting sources [2] [3]

Current clinical meaning

AOD-9604 is not an FDA-approved drug for obesity. A compounding discussion, ingredient listing or food-related safety claim is not approval of an injectable weight-loss medicine and does not overturn the unsuccessful obesity efficacy evidence.

Supporting sources [3]

Common questions

Did AOD-9604 demonstrate meaningful weight loss in its major obesity trial? FDA's review describes a large trial without statistically significant weight loss versus placebo. Animal metabolic findings do not overturn that result.

Is every vial called Fragment 176–191 chemically equivalent? No. AOD-9604 has a defined modified sequence; vendor shorthand alone cannot establish the identity or purity of another material.

Supporting sources [1] [2] [3] [4]